Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1970 1
1980 1
1981 3
1982 1
2002 1
2003 1
2006 1
2007 1
2012 2
2013 1
2015 1
2017 1
2018 4
2019 1
2020 1
2021 9
2022 6
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.
Nasser A, Hull JT, Chaturvedi SA, Liranso T, Odebo O, Kosheleff AR, Fry N, Cutler AJ, Rubin J, Schwabe S, Childress A. Nasser A, et al. Among authors: hull jt. CNS Drugs. 2022 Aug;36(8):897-915. doi: 10.1007/s40263-022-00938-w. Epub 2022 Jul 27. CNS Drugs. 2022. PMID: 35896943 Free PMC article. Clinical Trial.
Predicting efficacy of viloxazine extended-release treatment in adults with ADHD using an early change in ADHD symptoms: Machine learning Post Hoc analysis of a phase 3 clinical trial.
Faraone SV, Gomeni R, Hull JT, Chaturvedi SA, Busse GD, Melyan Z, O'Neal W, Rubin J, Nasser A. Faraone SV, et al. Among authors: hull jt. Psychiatry Res. 2022 Dec;318:114922. doi: 10.1016/j.psychres.2022.114922. Epub 2022 Oct 23. Psychiatry Res. 2022. PMID: 36375329 Free article. Clinical Trial.
Authors' Reply to Singh and Balasundaram: Comment on "A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder".
Nasser A, Hull JT, Liranso T, Fry N, Cutler AJ, Rubin J, Childress A. Nasser A, et al. Among authors: hull jt. CNS Drugs. 2022 Dec;36(12):1333-1335. doi: 10.1007/s40263-022-00967-5. Epub 2022 Nov 4. CNS Drugs. 2022. PMID: 36331781 Free PMC article. Clinical Trial. No abstract available.
A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Busse GD, Chowdhry F, Cutler AJ, Jones NJ, Findling RL, Schwabe S. Nasser A, et al. Among authors: hull jt. J Clin Psychopharmacol. 2021 Jul-Aug 01;41(4):370-380. doi: 10.1097/JCP.0000000000001404. J Clin Psychopharmacol. 2021. PMID: 34181360 Free PMC article. Clinical Trial.
38 results